Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.

Pharmaceuticals (Basel) · 2025 · PMC12114780 · PMID 40430547

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although interim overall survival analysis did not reach statistical significance, there was an overall benefit observed for the inavolisib group with an HR of 0.64 (95% CI: 0.43–0.97).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.